Intravenous pharmacokinetics and metabolism of the reactive oxygen scavenger α-phenyl-N-tert-butyl nitrone (PBN) in the cynomolgus monkey

Drug Metabolism and Drug Interactions

Volumn 20, Issue 1-2, 2004, Pages 11-24

  Lame, Mary E ^a,b   Kalgutkar, Amit S ^a   LaFontaine, Michael ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b CENTRAL CONNECTICUT STATE UNIVERSITY   (United States)

Author keywords

Antioxidant; Cytochrome P450; Monkey; PBN; Pharmacokinetics

Indexed keywords

ANTIOXIDANT; N TERT BUTYL ALPHA PHENYLNITRONE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SCAVENGER;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CATALYSIS; DOSE TIME EFFECT RELATION; DRUG METABOLISM; ENZYME ACTIVITY; HALF LIFE TIME; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALE; MASS SPECTROMETRY; MONKEY; NONHUMAN; PROTEIN BINDING; RAT; URINARY EXCRETION;

EID: 3242672600     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/DMDI.2004.20.1-2.11     Document Type: Article

References (21)

1. Kotake Y. Pharmacological properties of phenyl N-tert-butylnitrone. Antioxid Redox Signal 1999; 1: 481-499.
2. Floyd RA, Hensley K, Forster MJ, Kelleher-Anderson JA, Wood PL. Nitrones as neuroprotectants and antiaging drugs. Ann NY Acad Sci 2002; 959: 321-329.
3. Hensley K, Floyd RA. Reactive oxygen species and protein oxidation in aging: a look back, a look ahead. Arch Biochem Biophys 2002; 397: 377-383.
4. Kotake Y, Sang H, Miyajima T, Wallis GL. Inhibition of NF-κB, iNOS mRNA, COX2 mRNA, and COX catalytic activity by phenyl-N-tert-butylnitrone (PBN). Biochim Biophys Acta 1998; 1448: 77-84.
5. Fevig TL, Bowen SM, Janowick DA, Jones BK, Munson HR, Ohlweiler DF, Thomas CE. Design, synthesis, and in vitro evaluation of cyclic nitrones as free radical traps for the treatment of stroke. J Med Chem 1996; 39: 4988-4996.
6. Thomas CE, Bernardelli P, Bowen SM, Chaney SF, Friedrich D, Janowick DA, Jones BK, Keeley FJ, Kehne JH, Ketteler B, Ohlweiler DF, Paquette LA, Robke DJ, Fevig TL. Cyclic nitrone free radical traps: isolation, identification, and synthesis of 3,3-dimethyl-3,4-dihydroisoquinolin-4-ol N-oxide, a metabolite with reduced side effects. J Med Chem 1996; 39: 4997-5004.
7. Chen GM, Bray TM, Janzen EG, McCay PB. Excretion, metabolism and tissue distribution of a spin trapping agent, alpha-phenyl-N-tert-butyl-nitrone (PBN) in rats. Free Radic Res Commun 1990; 9: 317-323.
8. Trudeau-Lame ME, Kalgutkar AS, LaFontaine M. Pharmacokinetics and metabolism of the reactive oxygen scavenger alpha-phenyl-N-tert-butylnitrone in the male Sprague-Dawley rat. Drug Metab Dispos 2003; 31: 147-152.
9. Chen GM, Bray TM, Janzen EG, McCay PB. The role of mixed function oxidase (MFO) in the metabolism of the spin trapping agent alpha-phenyl-N-tert-butyl- nitrone (PBN) in rats. Free Rad Res Commun 1991; 14: 9-16.
10. Floyd RA. Protective action of nitrone based free radical traps against oxidative damage of the central nervous system. In: Sies H, ed. Advances in Pharmacology. San Diego, CA: Academic Press, 1996; 361-378.
11. Carney JM, Starke-Reed PE, Oliver CN, Landum RW, Cheng MS, Wu JF, Floyd RA. Reversal of age-related increase in brain protein oxidation, decrease in enzyme activity, and loss in temporal and spatial memory by chronic administration of the spin-trapping compound N-tert-butyl-alpha-phenylnitrone. Proc Natl Acad Sci USA 1991; 88: 3633-3636.
12. Janzen EG, West MS, Poyer JL. Comparison of antioxidant activity of PBN with hindered phenols in initiated rat liver microsomal lipid peroxidation. In: Asada K, Yoshikawa T, eds. Frontiers of Reactive Oxygen Species in Biology and Medicine. New York: Elsevier Science, 1994; 431-446.
13. Verhagen H, Beckers HH, Comuth PA, Maas LM, ten Hoor F, Henderson PT, Kleinjans JC. Disposition of single oral doses of butylated hydroxytoluene in man and rat. Food Chem Toxicol 1989; 27: 765-772.
14. Dautry C, Conde F, Brouillet E, Mittoux V, Beal MF, Bloch G, Hantraye P. Serial 1H-NMR spectroscopy study of metabolic impairment in primates chronically treated with succinate dehydrogenase inhibitor 3-nitropropionic acid. Neurobiol Dis 1999; 6: 259-268.
15. Palfi S, Ferrante RJ, Brouillet E, Beal MF, Dolan R, Guyot MC, Peschanski M, Hantraye P. Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. J Neurosci 1996; 16: 3019-3025.
16. Omura T, Sato R. The carbon monoxide binding pigment of liver microsomes. J Biol Chem 1964; 239: 3137-3142.
17. Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 1994; 47: 1469-1479.
18. Pang KS, Rowland M. Hepatic clearance of drugs, 1. Theoretical considerations of a "well-stirred" model and a "Parallel tube" model. Influence of hepatic blood flow, plasma, and blood cell binding and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 1977; 5: 625.
19. Benet LZ, Galeazzi RL. Noncompartment determination of the steady state volume of distribution. J Pharm Sci 1979; 68: 1071-1074.
20. Komori M, Kikuchi O, Sakuma T, Funaki J, Kitada M, Kamataki T. Molecular cloning of monkey liver cytochrome P-450 cDNAs: similarity of the primary sequences to human cytochromes P-450. Biochim Biophys Acta 1992; 1171: 141-146.
21. Reinke LA, Moore DR, Sang H, Janzen EG, Kotake Y. Aromatic hydroxylation in PBN spin trapping by hydroxyl radicals and cytochrome P-450. Free Radic Biol Med 2000; 28: 345-350.